Epstein-Barr virus (EBV) causes infectious mononucleosis in adolescents and malignant B lymphocyte proliferation in AIDS patients and patients undergoing immune suppression for organ transplantation. EBV is etiologically associated with African Burkitt's lymphoma (BL), Hodgkin's lymphoma (HL) and nasopharyngeal carcinoma (NPC). In vitro, EBV transformed, latently infected B lymphocytes contain EBV episomes and nine virus encoded proteins. Six are nuclear proteins (EBNAs) and three are the integral membrane proteins, LMP1, LMP2A, and LMP2B. These nine proteins are presumed to mediate latent virus infection or B lymphocyte proliferation and thus are under intense investigation. Besides EBNA1, which is required for episome maintenance, LMP1, LMP2A, and LMP2B are the latently expressed proteins consistently detected in EBV related malignancies and EBV-associated diseases in HIV/AIDS patients. Currently, studies designed to elucidate LMP2A function in vitro are hampered by the need to use continuous cell lines or EBV transformed lymphoblastoid cell lines (LCLs) that do not reflect the unactivated B lymphocyte in which EBV is latent in the human host. To begin to understand the function of LMP2A in latent infection, we have developed a murine transgenic model system that targets LMP2A expression to B lymphocytes. The model has proved useful in characterizing the alteration of normal B cell function by LMP2A and has proved invaluable in investigating the requirements for LMP2A function in latent infection. This model has also provided clues in regard to how LMP2A may contribute to EBV-associated disease in HIV/AIDS patients. In the current proposal, we will continue our analysis of LMP2A function in our transgenic mice using both in vitro and in vivo techniques. An understanding of LMP2A function may provide insight for the development of novel therapeutics for the treatment or eradication of EBV latent infections in the human host, thereby lessening EBV-associated lymphoproliferative disease and other EBV- related pathologies in HIV/AIDS patients and in patients with immune dysfunction such as those undergoing immune suppression for organ transplantation.
Our specific aims are to identify cellular and viral factors that are important for Epstein-Barr virus (EBV) latent infections and EBV-associated hematological cancers and proliferative disorders that occur in the human host and those in particular that occur in HIV/AIDS patients. An understanding of how EBV contributes to EBV lymphoproliferative disease and other EBV-related pathologies in HIV/AIDS patients may provide insight for the development of novel therapeutics for the treatment or eradication of EBV-associated disease in HIV/AIDS patients, the ultimate goal of our studies.
|Rink, Jonathan S; Yang, Shuo; Cen, Osman et al. (2017) Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin. Mol Pharm 14:4042-4051|
|Fish, Kamonwan; Sora, Richard P; Schaller, Samantha J et al. (2017) EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice. Blood 130:2516-2526|
|Yigit, Burcu; Halibozek, Peter J; Chen, Shih-Shih et al. (2016) A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget 7:26346-60|
|Fish, Kamonwan; Chen, Jia; Longnecker, Richard (2014) Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 123:530-40|
|Brägelmann, J; Dagogo-Jack, I; El Dinali, M et al. (2013) Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol 49:525-33|
|Shim, Ann Hye-Ryong; Chang, Rhoda Ahn; Chen, Xiaoyan et al. (2012) Multipronged attenuation of macrophage-colony stimulating factor signaling by Epstein-Barr virus BARF1. Proc Natl Acad Sci U S A 109:12962-7|
|Vrazo, Alexandra C; Chauchard, Maria; Raab-Traub, Nancy et al. (2012) Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice. PLoS Pathog 8:e1002662|
|Chang, Rhoda A; Miller, Stephen D; Longnecker, Richard (2012) Epstein-Barr virus latent membrane protein 2A exacerbates experimental autoimmune encephalomyelitis and enhances antigen presentation function. Sci Rep 2:353|
|Dargart, Jamie L; Fish, Kamonwan; Gordon, Leo I et al. (2012) Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res 95:49-56|
|Cen, Osman; Longnecker, Richard (2011) Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma. Mol Cancer Ther 10:679-86|
Showing the most recent 10 out of 76 publications